SCHEMBL1149045

SCHEMBL1149045

CC(=O)Nc1ncc2cc(-c3cc(C(=O)Nc4cccc(C(F)(F)F)c4)ccc3C)c(O)c(-c3ccc(F)nc3)c2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.56
MAPK14 Q16539 10/20 0.56
LCK P06239 8/20 0.56
JAK3 P52333 5/20 0.56
TEK Q02763 3/20 0.56
BRAF P15056 3/20 0.56
KIT P10721 6/20 0.55
DDR2 Q16832 5/20 0.50
SYK P43405 2/20 0.47
SRC P12931 1/20 0.47
TYK2 P29597 1/20 0.47
MAPK8 P45983 1/20 0.47
MAPK9 P45984 1/20 0.47
MAPK10 P53779 1/20 0.47
BTK Q06187 1/20 0.47
DDR1 Q08345 3/20 0.46
ABL1 P00519 2/20 0.46
BCR P11274 2/20 0.46
MAPK13 O15264 1/20 0.46
LYN P07948 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1079204 0.93 KDR (0.56) KDRMAPK14LCKJAK3TEK
SCHEMBL1149064 0.93 LCK (0.65) KDRMAPK14LCKJAK3TEK
SCHEMBL1077383 0.93 KDR (0.54) KDRMAPK14LCKJAK3TEK
SCHEMBL1076762 0.91 LCK (0.54) KDRMAPK14LCKJAK3TEK
SCHEMBL1078899 0.91 LCK (0.64) KDRMAPK14LCKJAK3TEK
SCHEMBL1077787 0.90 LCK (0.53) KDRMAPK14LCKJAK3TEK
SCHEMBL1083477 0.88 KDR (0.55) KDRMAPK14LCKJAK3TEK
SCHEMBL1078797 0.87 BRAF (0.50) KDRMAPK14LCKJAK3TEK
SCHEMBL1149308 0.87 DDR2 (0.59) KDRMAPK14LCKJAK3TEK
SCHEMBL1079322 0.86 KDR (0.61) KDRMAPK14LCKJAK3TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2269993-B1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO LTD (JP) 2013-02-27 EP disclosed
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE H1-2, H1-3, H1-0 KDR 896/4885MAPK14 2338/4885LCK 3187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.